AMPHOTEC Drug Patent Profile
When do Amphotec patents expire, and when can generic versions of Amphotec launch?
Amphotec is a drug marketed by Alkopharma Usa and is included in one NDA.
The generic ingredient in AMPHOTEC is amphotericin b. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amphotec
A generic version of AMPHOTEC was approved as amphotericin b by XGEN PHARMS on April 29th, 1992.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AMPHOTEC?
- What are the global sales for AMPHOTEC?
- What is Average Wholesale Price for AMPHOTEC?
Summary for AMPHOTEC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 1 |
| DailyMed Link: | AMPHOTEC at DailyMed |
Recent Clinical Trials for AMPHOTEC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1/Phase 2 |
US Patents and Regulatory Information for AMPHOTEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkopharma Usa | AMPHOTEC | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050729-001 | Nov 22, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alkopharma Usa | AMPHOTEC | amphotericin b | INJECTABLE, LIPID COMPLEX;INJECTION | 050729-002 | Nov 22, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
